BofA Upgrades ICON to Neutral Amid Improved CRO Demand and Better Visibility
Morgan Stanley analyst Filippo Bacci upgraded ICON Public Limited Co (ICLR) from underweight to neutral, citing stronger demand for contract research organization services. The upgrade is based on improved visibility into the company's performance through 2027, driven by rising R&D spending among top biopharma firms. Analysts estimate that the industry’s leading companies will increase their R&D budgets by approximately 4% in 2027. The shift reflects growing confidence in ICON's ability to benefit from this trend and deliver better-than-expected results over the next few years. The upgrade suggests a more favorable outlook for the company, which could influence investor sentiment toward its stock positively as demand for CRO services continues to rise across the biopharma sector.
Tickers: $ICLR
Topics: Biotech R&D CRO Services Pharmaceuticals